Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06629506 · ClinicalTrials.gov registry record · NA
MicroMatrix® Flex in Tunneling Wounds
A NA study, sponsored by Integra LifeSciences Corporation.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT06629506 is a NA study that has completed, run by Integra LifeSciences Corporation. The registered enrollment target is 25 participants.
The verdict
NCT06629506, a NA study, has completed, sponsored by Integra LifeSciences Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
To evaluate the safety and performance of MicroMatrix® Flex in subjects with wounds complicated by tunneling and/or undermining features.
Interventions
- DEVICE MicroMatrix® Flex
- DEVICE MicroMatrix® UBM Particulate
- DEVICE Cytal® Wound Matrix 2-Layer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-12-12 |
| Est. Completion | 2025-08-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06629506
The ClinicalTrials.gov registry entry for NCT06629506 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Integra LifeSciences Corporation, which has 60 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which MicroMatrix® Flex is the first listed.
NCT06629506 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06629506 about?
NCT06629506 is a clinical study titled "MicroMatrix® Flex in Tunneling Wounds". To evaluate the safety and performance of MicroMatrix® Flex in subjects with wounds complicated by tunneling and/or undermining features.
What is the current status of trial NCT06629506?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2024-12-12. Estimated completion is 2025-08-31.
What interventions are being tested in trial NCT06629506?
The interventions under investigation include: MicroMatrix® Flex (DEVICE), MicroMatrix® UBM Particulate (DEVICE), Cytal® Wound Matrix 2-Layer (DEVICE).
Who is sponsoring clinical trial NCT06629506?
This trial is sponsored by Integra LifeSciences Corporation, which has 60 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.